- Market Capitalization, $K 3,640,868
- Shares Outstanding, K 86,154
- Annual Sales, $ 212,960 K
- Annual Income, $ -86,420 K
- 60-Month Beta 1.75
- Price/Sales 17.10
- Price/Cash Flow N/A
- Price/Book 7.16
|Period||Period Low||Period High||Performance|
| || |
+6.69 (+18.81%)since 05/24/19
| || |
-12.18 (-22.37%)since 03/26/19
| || |
-19.09 (-31.12%)since 06/26/18
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that Chief Executive Officer Thomas B. Neff will...
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Suzanne Blaug as an independent...
Investors in FibroGen Inc saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FGEN options chain for...
Opportunity to build retail store and online sales expands distribution footprint
Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $38.62 to a high of $38.95. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $38.20...
SmarTrend identified a Downtrend for Fibrogen Inc (NASDAQ:FGEN) on March 8th, 2019 at $54.15. In approximately 2 months, Fibrogen Inc has returned 32.90% as of today's recent price of $36.34.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN).
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $34.65 to a high of $37.91. Yesterday, the shares fell 24.1%, which took the trading range below the 3-day low of $45.19...
FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?